<DOC>
	<DOCNO>NCT02806011</DOCNO>
	<brief_summary>This 3-year ( +30 day ) long term follow study evaluate safety Livercellgram subject participate complete Livercellgram Phase 2 trial ( refer ClinicalTrials.gov.Identifier : NCT01875081 ) . This trial plan evaluate safety Livercellgram patient alcoholic liver cirrhosis . Subjects sign follow-up observation inform consent form participate safety assessment ( tumor marker test , occurrence adverse event serious adverse event , clinical laboratory test , vital sign , physical examination . ) .</brief_summary>
	<brief_title>Long-term Follow-up Study Livercellgram Alcoholic Liver Cirrhosis Patients Who Completed Livercellgram Phase 2 Study</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis , Alcoholic</mesh_term>
	<criteria>1 . Subjects treat Livercellgram complete Livercellgram phase 2 study . 2 . Subjects agree participate long term observation study oneself .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>